Kura Oncology Secures $135 Million Milestone Payment from Kyowa Kirin
Reuters
Dec 02, 2025
<a href="https://laohu8.com/S/KURA">Kura Oncology</a> Secures $135 Million Milestone Payment from Kyowa Kirin
Kura Oncology Inc. announced the completion of the first U.S. commercial sale of KOMZIFTI™ (ziftomenib), following its FDA approval on November 13, 2025. This sale has triggered a $135 million milestone payment to Kura under its collaboration and license agreement with Kyowa Kirin Co. Ltd. and Kyowa Kirin, Inc. Kura expects to receive the payment before the end of the year.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kura Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9595053-en) on December 02, 2025, and is solely responsible for the information contained therein.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.